期刊文献+

内毒素结合肽及其突变体的表达纯化和抗内毒素/脂多糖活性研究 被引量:3

Study on the expression,purification and the anti-endotoxin activity of human endotoxin binding peptide and its mutant
原文传递
导出
摘要 目的使内毒素结合肽(EBP)及其突变体mEBP在E.coli DH5α中表达,纯化后鉴定其抗内毒素/脂多糖(LPS)活性。方法(1)将含PinpointXa3-EBP及其突变体PinpointXa3-mEBP的工程菌DH5α活化,加入异丙硫半乳糖苷(IPTG)诱导其表达生物素融合蛋白。分离纯化表达产物,因子Xa酶切融合蛋白分离目的肽EBP和mEBP。采用亲和层析及反相高效液相色谱法纯化目的肽,用氨基末端10个氨基酸残基序列分析法鉴定突变体mEBP。(2)分离正常人外周血单核细胞(PBMC),用5 mg/L异硫氰酸荧光素(FITC)-LPS+不同浓度EBP或mEBP(均为2.0、5.0、12.5 mg/L)刺激PBMC,检测其平均荧光强度。用1 mg/L LPS+3种浓度(同前)EBP或mEBP刺激PBMC,5 h后取上清液,检测肿瘤坏死因子(TNF)α和白细胞介素(IL)6浓度。(3)将25只昆明小鼠分为正常对照组(5只):腹腔注射等渗盐水0.2 ml;模型组(5只):小鼠造成20%TBSAⅢ度烧伤,伤后腹腔注射LPS(1 mg/kg);治疗组(15只):小鼠同前致伤后,腹腔注射多黏菌素B(PMB,5 mg/kg)或EBP或mEBP(后两者均为10 mg/kg)。6 h后检测各组小鼠血清TNF-α、IL-6浓度及肝组织中TNF-αmRNA的表达水平。结果(1)纯化后的目的肽EBP、mEBP纯度均达98%以上,mEBP氨基末端10个氨基酸残基序列分析符合预期结果。(2)随着mEBP或EBP浓度的增加,PBMC表面的平均荧光强度逐渐减弱;且在同一浓度下,加入mEBP后平均荧光强度的减弱程度较加入EBP明显。与用1 mg/L LPS刺激PBMC比较,加入1 mg/L LPS+12.5 mg/L EBP以及1 mg/L LPS+3种浓度mEBP刺激后, PBMC培养上清液中IL-6及TNF-α的水平均明显降低(P<0.01)。(3)与模型组比较,治疗组小鼠血清IL-6、TNF-α水平均明显降低(P<0.01),其中10 mg/kg mEBP治疗组两指标低于等浓度EBP治疗组(P<0.05)。(4)小鼠肝组织TNF-αmRNA表达水平:正常对照组相对灰度值为0.25,模型组为0.93,10 mg/kg mEBP治疗组为0.51,10 mg/kg EBP治疗组为0.77,5 mg/kg PMB治疗组为0.43。结论具有抗LPS活性的小分子肽可通过原核表达获得;EBP及mEBP均具有抗LPS活性,其中mEBP拮抗作用更强。 Objective To express endotoxin binding peptide and its mutant in E coli DH5α and detect the antiendotoxin activity of the purified peptides. Methods ( 1 ) E coli DH5αt containing pinpointXa3- EBP and pinpointXa3-mEBP was activated by IPTG to express biotin fusion protein. The fusion proteins were purified, and then digested by factor Xa for isolation of EBP and mEBP. The target peptide was purified with affinity chromatography and reversed-phase HPLC. Sequences of 10 amino acids at N-terminal were used for identification of mEBP. (2) PBMCs were isolated from blood of normal people, and they were stimulated with 5 mg/L FITC-LPS plus 2.0,5.0 and 12.5 mg/L EBP or mEBP. Then the mean fluorescent intensity was detected. PBMC was also stimulated with 1 mg/L LPS plus 2.0, 5.0 and 12.5 mg/L EBP or mEBP for 5 hours for the detection of the TNF-α and IL-6 level in the supernatant. (3) Thirty-five Kunming mice were randomized into normal control ( n = 5, with intraperitoneal injection of 0.2 ml isotonic saline) , model group(n = 5, with intraperitoneal injection of LPS and 20% TBSA full-thickness burns) , and treatment group ( n = 15, with intraperitoneal injection of 5 mg/kg PMB or 10 mg/kg EBP or mEBP after burns). The serum contents of TNF-α and IL-6, and TNF-α mRNA level in hepatic tissue in each group were determined 6 hours after treatment. Results ( 1 ) EBP and mEBP were obtained after Xa digestion of biotin fusion protein, with purity reaching above 98%. The sequence of 10 amino acid at N-terminal was in accord with what expected. (2) The fluorescent intensity was decreased followed by an increase in mEBP or EBP concentration. Compared with normal PMBC, IL-6 and TNF-α level in the supernatant were obviously lowered in 1 mg/L LPS+12.5 mg/L EBP group and 1 mg/L LPS+2.0 , 5.0, 12.5 mg/L mEBP groups ( P 〈 0. 01 ). (3) The serum level of IL-6 and TNF-α in the therapeutic groups were obviously lower than that in model group ( P 〈0. 01 ) , and the levels of these cytokines were significantly lower in 10 mg/kg mEBP group than that in 10 mg/kg EBP group ( P 〈0.01 ) , but they were similar to that in 5 mg/kg PMB treatment group ( P 〉0.05). (4) Relative optical density of TNF-α mRNA in control, model, 10 mg/kg mEBP, 10 mg/kg EBP and 5 mg/kg PMB groups was 0. 25, 0. 93, 0. 51, 0. 77 and 0. 43, respectively. Conclusion Endotoxin binding peptides can be obtained by procaryon expression. Both EBP and mEBP have anti-LPS activity, but mEBP is more effective.
出处 《中华烧伤杂志》 CAS CSCD 北大核心 2006年第4期291-295,共5页 Chinese Journal of Burns
关键词 基因表达 内毒素类 内毒素结合肽 突变体 纯化 Gene expression Endotoxin Endotoxin binding peptide Mutant Purification
  • 相关文献

参考文献9

  • 1Cohen J.The immunopathogenesis of sepsis.Nature,2002,420:885-891.
  • 2Edwin S,Van A,Theo JC,et al.Receptors,mediators,and mechanisms involved in bacterial sepsis and septic shock.Clin Microb Rev,2003,16:379-414.
  • 3Arana MJ,Vallespi MG,Chinea G,et al.Inhibition of LPS-responscs by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction.J Endotoxin Res,2003,9:281-291.
  • 4麻莉,刘友生,王晓东,李永旺.内毒素结合肽的原核表达、纯化及生物学活性鉴定[J].中国生物化学与分子生物学报,2004,20(4):479-483. 被引量:5
  • 5Smbrook J,Russell DW,主编.分子克隆实验指南.黄培堂,译.第3版.北京:科学出版社,2002.1228-1231.
  • 6Wasiluk KR,Leslie DB,Vietzen PS,et al.Structure/function studies of an endotoxin -neutralizing peptide derived from bactericidal/permeability-increasing protein.Surgery,2004,136:253 -260.
  • 7Kellogg TA,Lazaron V,Wasiluk KR,et al.Binding specificity of polymyxin B,BPI,LALF,and anti-deep core/lipid a monoclonal antibody to lipopolysaccharide partial structures.Shock,2001,15:124-129.
  • 8Caroff M,Karibian D.Structure of bacterial lipopolysaccharides.Carbohydrate Researc,2003,338:2431-2447.
  • 9Lopez-Bojorquez LN,Dehesa AZ,Reyes-Teran G.Molecular mechanisms involved in the pathogenesis of septic shock.Arch Med Res,2004,35:465 -479.

二级参考文献10

  • 1Calafat J, Janssen H, Knol EF, Malm J, Egesten A. The bactericidal/permeability increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. Acta Pathol Microbiol Immunol Scand
  • 2Dankesreiter S, Hoess A, Schneider-Mergener J, Wagner H, Miethke T.Synthetic endotoxin binding peptides block enendotoxin triggered TNFalpha production by maerophages in vitro and in vivo and proevent endotoxin mediated toxic shock. J Immunol, 2000,164 (9
  • 3Besmer-LJ, et al. The BPI/LBP family of proteins: a structureal analysis of conserved regions. Protein Sci, 1998,7 ( 4 ): 906 - 910
  • 4Kellogg TA, Weiss CA, Johnson JW, Schmitz, G, Aslanidis, C.Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J Surg Res, 1999,85( 1 ): 136 - 141
  • 5Reyes O, Vallespi M G, Garay H E, Wagner H, Miethke T, Francot G J,Buurman W A. Identification of single amino acid residues essential for the binding of lipopolysaccharide (LPS)to LPS binding protein (LBP)residues 86-99 by using an Ala-scanning library.
  • 6Schumann R R, Leong S R, Flaggs G W, Gray P W; Wright S D;Mathison P S; Richard T. Structure and function of lipopolysaccaride binding protein. Science, 1990,249(4975): 1429 - 1431
  • 7Lesley S A, Groskreutz D J. Simple affinity purification of antibodies using in vivo biotinylation of a fusion protein. J Immunol Methods,1997,207(2): 147 - 155
  • 8Nagahira A, Nagabira K, Murafuji H, Abe, K, Magota, K, Matsui, M.Identification of a novel inhibitior of LPS-induced TNF-alpha production with antiprolfferative activity in monocyte/macrophages. Biochem Biophys Res Commun ,2001,281(4): 1030 ~ 1036
  • 9Molly R G,Mannick J A,Rodrick M L,Vermeulen M W,Zanzot E M,Warren H S. C ytokines, sepsis and immunomodulation. Br J Surg, 1993,80(3) :289 - 297
  • 10麻莉 刘友生 王晓东 李永旺 葛晓冬.内毒素结合肽EBP基因的克隆及其表达质粒的构建[J].解放军医学杂志,.

共引文献6

同被引文献36

  • 1Arana Mde J,Va llespi MG,Chinea G,et al.Inhibition ofLPS-responses by synthetic peptides derived from LBPassociates with the ability of the peptides to block LBP-LPSinteraction[J].J Endotoxin Res,2003,9(5):281-291.
  • 2Taylor AH,Heavner G,Nedelman M,et al.Lipopolysaccharideneutralizing peptides reveal a lipid A binding site of LPSbinding protein[J].J Biol Chem,1995,270(30):17934-17938.
  • 3Reyes O,Vallespi MG,Garay HE,et al.Identification ofsingle amino acid residues essential for the binding oflipopolysaccharide(LPS)to LPS binding protein(LBP)residues 86-99 by using an Ala-scanning library[J].J PeptSci,2002,8(4):144-150.
  • 4Su GL,Hoesel LM,Bayliss J,et al.Lipopolysaccharidebinding protein inhibitory peptide protects againstacetaminophen-induced hepatotoxicity[J].Am J PhysiolGastrointest Liver Physiol,2010,299(6):G1319-G1325.
  • 5Bhattacharjya S.De novo designed lipopolysaccharidebinding peptides:structure based development ofantiendotoxic and antimicrobial drugs[J].Curr Med Chem,2010,17(27):3080-3093.
  • 6Wong KF,Luk JM.Endotoxin-neutralizing peptides asgram-negative sepsis therapeutics[J].Protein Pept lett,2009,16(5):539-542.
  • 7Wasiluk KR,Leslie DB,Vietzen PS,et a1.Structure/functionstudies of an endotoxin-neutralizing peptide derived frombactericidal/permeability-increasing protein[J].Surgery,2004,136(2):253-260.
  • 8Perel A,Segal E.Management of sepsis[J].N Engl J Med,2007,356(11):1178-1182.
  • 9Ulloa L,Tracey KJ.The"cytokine profile":a code for sepsis[J].Trends Mol Med,2005,11(2):56-63.
  • 10Wong KF,Luk JM.Endotoxin-neutralizing peptides as gram-negativesepsis therapeutics[J].Protein Pept Lett,2009,16(5):539-542.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部